

Mr FJZ
5/20
~~138. (Amended) The method of claim 132, wherein said epidermal growth factor-like [factor like] domain comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, [and] SEQ ID NO: 159, and SEQ ID NO: 191.~~

Add the following new claim.

Subj 3
~~141. The method of claim 132, wherein said epidermal growth factor-like domain comprises an amino acid sequence set forth in SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 190.~~

In the Drawings:

Replace the drawings, Figs. 1-54, with the substitute drawings, Figs. 1-54, provided herewith.

REMARKS

The communication mailed December 8, 1998 states that claims 136-137 fail to comply with 37 CFR 1.822(o) (a sequence that is made up of one or more noncontiguous segments of a larger sequence or segments from different sequences shall be presented as a separate sequence). As described below, the claims 136-137 have been amended and SEQ ID NOs: 188 and 189 have been added to the Sequence Listing to correct this informality.

In addition, the specification, drawings, and claims have been amended. The amendments were made in order to correct typographical errors, insert SEQ ID NOs. and Descriptions of the Drawings wherever these are lacking, and correct claim dependencies.

Support for the Amendments

The specification has been amended. Wherever the GGF2HBS5 polypeptide (GGF-II) was misidentified in the original specification as SEQ ID NO: 167, the polypeptide is now correctly identified as SEQ ID NO: 170. Such amendment is made on page 7, line 16, page 32, lines 28-29, and page 66, lines 27-29, of the specification. Support for the foregoing amendment to the GGF-II polypeptide SEQ ID NO (from 167 to 170) may be found, e.g., on page 33, lines 28-29, of the specification.

Substitute drawings are provided for the purpose of clarity and to correct typographical errors (specifically, in Figs. 31I-31L). In addition, several of the replacement drawings are now subdivided: for example, Fig. 31 is now divided into Figs. 31A-31R. Corrections to the descriptions of the drawings are made to reflect these subdivisions.

New SEQ ID NOs., 185-187 and 192, have inserted into the specification at pages 13 and 61. The peptides now assigned these SEQ ID NOs. were present in the original disclosure, but had not previously been assigned SEQ ID NOs. SEQ ID NOs. 185-187 and 192 also have been added to the Sequence Listing.

Claims 136-138 have been amended, new claim 141 has been added, and claims 133-135 have been canceled. Claims 136 and 137, which previously depended from claim 133 (now canceled), now depend from claim 132.

As required under 37 C.F.R. § 1.822 (o), claims 136 and 137 have been amended to recite new SEQ ID NOs (SEQ ID NOS: 188 and 189) that set forth the linked subsequences previously recited as separate sequences. In concert with the amendment to claims 136 and 137, the Sequence Listing has been amended to contain these two new sequences, which consist of joined sequences present in the original sequence listing in an

order described in the originally-filed specification. Hence, no new matter is added. Support for new SEQ ID NO: 188 (as provided in claim 136) comes from its subsequences, SEQ ID NO: 177 (C-segment) and SEQ ID NO: 42 (C/D'-segment), found in the original Sequence Listing. Similarly, support for new SEQ ID NO: 189 (claim 137) comes from its subsequences, SEQ ID NO: 177 (C-segment), SEQ ID NO: 42 (C/D'-segment), and SEQ ID NO: 144 (D-segment), found in the original Sequence Listing. The orientation of the sequences, as claimed, is shown in Fig. 30, and is described in the specification on page 8, lines 3 through 16. Supporting language for the amendments to claim 136 may be found within Figures 31G, 31I, and within the amended Sequence Listing. Similarly, supporting language for the amendments to claim 137 may be found within Figures 31G, 31I, 31J, and within the amended Sequence Listing.

Claim 138 now recites the EGF-like domain encoded by new SEQ ID NO: 191 (amino acids 54-103 encoded by SEQ ID NO: 150). Support for the inclusion of this EGF-like domain may be found, e.g., at page 65, lines 1 through 8 and at Fig. 34 (SEQ ID NO: 150), of the specification.


New claim 141 recites the EGF-like domains set forth in SEQ ID NOs: 151, 152, and new SEQ ID NO: 190 (amino acids 362-411 of SEQ ID NO: 170). Support for claim 141 may be found, e.g., at page 80, line 26, through page 81, line 12; at page 11, lines 18-21; at page 66, lines 16-21, and at Fig. 35.

No new matter has been introduced by the above amendments.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: January 8, 1999


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

04585.00200R reply to office commun.prelim amend..wpd